Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

Delayed Quote. Delayed  - 09/23 05:35:24 pm
97.89 EUR   +0.06%
09/22 MERCK : and the Royal Health Awareness Society Partner to Advance Wo..
09/21 MERCK : Invests over € 50 million in Flagship Pharmaceutical Packagi..
09/21 GLOBAL AZO PIGM : Basf, Clariant, Lanxess, Eckart, EMD, Merck KGaA, ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck KGaA Gives Details On Planned Efficiency Program

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/24/2012 | 05:51pm CEST

-- Germany's Merck provides details about efficiency program.

-- Conglomerate joins a long list of drug makers revamping themselves.

-- Merck KGaA shares fall after restructuring update.

(Adds details, share details, background.)

   By Neetha Mahadevan 
   Of  
 

Pharmaceutical and chemical company Merck KGaA (>> Merck KGaA) said Friday it launched a cost-cutting and efficiency plan in the wake of increased price pressures in the U.S. and Europe and a series of drug development setbacks.

The company said the plan could involve job cuts across all businesses and regions to reduce costs and address "unprecedented market shifts", but it didn't disclose details, saying management still needed to speak with relevant stakeholders for a mutually acceptable solution.

"Over the next two years, Merck needs to address unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization to ensure the long-term success of its business model," Chief Executive Karl-Ludwig Kley said in a statement.

With its new cost-cutting drive, the German chemical and pharmaceutical company joins a long list of other drug makers who are revamping themselves in response to falling sales and profitability.

The need to cut costs is partly due to mounting pressure stemming from health care reforms in the U.S. and Europe, where governments are increasingly reluctant to reimburse expensive drugs and advocate the use of cheaper generic medicines. Companies such as AstraZeneca Plc (AZ.LN), Novartis AG (NVS), Roche Holding AG (ROG.VX), Pfizer Inc (>> Pfizer Inc.), Eli Lilly & Co (>> Eli Lilly & Co.) have all embarked on cost saving or restructuring programs to keep costs under control.

In addition to set-backs in its drug pipeline, Merck has also been hit by a slowdown in demand at its chemicals division, which led to disappointing developments in the last year and prompted it to tighten its outlook time and again.

In the second-quarter, it recorded a 6.5% drop in revenue at its chemicals division, while in the third-quarter profits fell due largely to weakness in its performance materials division.

The efficiency measures are part of Merck's comprehensive transformation program, announced last year, and comprises two phases, the company said.

In the first two years, Merck plans to set up a new leadership organization, implement efficiency measures and focus on long-term growth, while the second phase will be focused on exploiting new growth opportunities, it added.

Merck KGaA shares fell after the news and at 1545 GMT traded down 1.2% at EUR79.70, while the DAX benchmark index traded 0.6% higher.

-By Neetha Mahadevan, Dow Jones Newswires; +49 69 2972 5507; neetha.mahadevan@dowjones.com

(Sten Stovall contributed to this article.)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
09/22 MERCK : and the Royal Health Awareness Society Partner to Advance Women's Health..
09/21 MERCK : Invests over € 50 million in Flagship Pharmaceutical Packaging Building ..
09/21 GLOBAL AZO PIGMENTS MARKET 2016 : Basf, Clariant, Lanxess, Eckart, EMD, Merck KG..
09/21 MERCK : Angola Receives 4 Million Praziquantel Tablets
09/20 MERCK : Prexton successfully completes phase 1 Parkinson's disease trial
09/19 MERCK : New Steritest™ Symbio Pump Accessories Enable Faster, Safer Steril..
09/16 MERCK : Presents New Data Examining Durable Efficacy with Investigational Cladri..
09/15 MERCK : Announces 2016 Recipients of € 1 Million Grant for Multiple Sclerosis In..
09/15 MERCK : Findings from Merck KGaA Broaden Understanding of Granular Matter Resear..
09/15 MERCK : "From Glitter to Glamour" – The Merck Pigment Innovation Ronastar®..
More news
Sector news : Specialty & Advanced Pharmaceuticals
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
08/19 ALPHA FROM EQUAL-WEIGHTING : A Look At Materials
08/10 Bristol's Opdivo Fall-Out Brings Others Into Play
08/05 Merck KGaA's (MKGAF) CEO Stefan Oschmann on Q2 2016 Results - Earnings Call T..
08/04 Merck KGaA reports Q2 results
07/18 Merck's marketing application for Cladribine tablets accepted for review in E..
Advertisement
Financials (€)
Sales 2016 15 041 M
EBIT 2016 3 285 M
Net income 2016 1 546 M
Debt 2016 10 800 M
Yield 2016 1,25%
P/E ratio 2016 25,90
P/E ratio 2017 22,47
EV / Sales 2016 1,56x
EV / Sales 2017 1,39x
Capitalization 12 652 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 104 €
Spread / Average Target 6,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA9.29%14 203
ABBVIE INC9.69%105 823
BIOGEN INC2.03%68 493
KYOWA HAKKO KIRIN CO L..-14.44%9 295
MALLINCKRODT PLC2.25%8 220
JAZZ PHARMACEUTICALS P..-9.51%7 699
More Results